Effects of probiotics on the gastrointestinal tract

Current Opinion in Infectious Diseases

Volumn 18, Issue 5, 2005, Pages 420-426

  Snelling, Anna M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Alternative therapeutics; Gastrointestinal disease; Gastrointestinal tract infection; Lactobacilli; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FUNGEMIA; GASTROINTESTINAL INFECTION; GENE EXPRESSION; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS REUTERI; NECROTIZING ENTEROCOLITIS; NONHUMAN; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS;

EID: 25144506978     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000182103.32504.e3     Document Type: Review

References (77)

1. Burton J, Chilcott C, Tagg J. The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis 2005; 11:29-31.
2. Nishijima K, Shukunami K, Kotsuji F. Probiotics affects vaginal flora in pregnant women, suggesting the possibility of preventing preterm labor. J Clin Gastroenterol 2005; 39:447-448.
3. Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses 2005; 64:533-538.
4. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16:658-672.
5. Leahy SC, Higgins DG, Fitzgerald GF, Sinderen D. Getting better with bifidobacteria. J Appl Microbiol 2005; 98:1303-1315. This is a highly detailed review of Bifidobacteria including their use for treating infectious and non-infectious gastrointestinal diseases, as well as characteristics and genomic analysis of the genus.
6. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004; CD003048. This makes essential reading for anyone with an interest in this topic. The report is available from the website http://www.mrw.interscience.wiley.com/cochrane/ clsysrev/articles/ CD003048/frame.html
7. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115:5-9. This relatively large scale (201 participants) study compared infant formula supplemented with a lactobacillus versus a bifidobacterium strain for preventing diarrhoea and respiratory illness. It was relatively unusual to have two different probiotics tested against placebo in the same trial.
8. Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr 2004; 39:147-152. The authors describe fewer cases of dehydration and medical consultations amongst infants taking the formula than controls. The incidence and duration of diarrhea were not significantly different.
9. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 2005; 94:44-47. This reports on positive benefits, with duration of diarrhoea significantly reduced in the S. boulardii group compared with the placebo group (4.7 versus 5.5 days, P = 0.03).
10. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004; 50:234-236. This was one of the first studies of S. boulardii for this indication in children. Patients received azithromycin or sulbactram-ampicillin.
11. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:583-590. This was one of the first studies of S. boulardii for this indication in children. Probiotic was beneficial for preventing AAD associated with antibiotics being administered for otitis media or respiratory infections.
12. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115:1-4. This demonstrated that a combination of probiotic strains (L. acidophilus and B. infantis) fed enterally with breast milk could help protect low birth weight infants from a life-threatening condition.
13. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004; 7:59-62.
14. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324:1361-1366.
15. Hoy CM, Wood CM, Hawkey PM, Puntis JW. Duodenal microflora in very-low-birth-weight neonates and relation to necrotizing enterocolitis. J Clin Microbiol 2000; 38:4539-4547.
16. Dani C, Biadaioli R, Bertini G, et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002; 82:103-108.
17. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999; 3:197-202.
18. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy: a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005; 21: 1263-1272.
19. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2004; 20:1181-1188.
20. Tursi A, Brandimarte G, Giorgetti GM, Modeo ME. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 2004; 10:CR662-CR666.
21. Wang KY, Li SN, Liu CS, et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004; 80:737-741.
22. Langlands SJ, Hopkins MJ, Coleman N, Cummings JH. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004; 53:1610-1616. This was a significant study of the effects prebiotics can have on different components of the gut flora because biopsies were obtained from caecum, colon and rectum of live, human volunteers for analysis.
23. Ouwehand AC, Derrien M, de Vos W, et al. Prebiotics and other microbial substrates for gut functionality. Curr Opin Biotechnol 2005; 16:212-217. This is a useful starting point for anyone new to the concept of prebiotics.
24. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: A randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3:442-448. This demonstrates the efficacy of a cheap and simple approach for a common problem associated with C. difficile infection and treatment.
25. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54:242-249. Inflammation was assessed both by transcription levels of a variety of immune markers and sigmoidoscopy. A beneficial effect was clearly evident after 1 month.
26. Jain PK, McNaught CE, Anderson AD, et al. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Clin Nutr 2004; 23:467-475. There was no significant difference in gut barrier function as assessed via permeability to lactulose/rhamnose. The rate of septic complications or mortality was also similar, but it is noteworthy that the synbiotic group had lower incidence of pathogens in nasogastric aspirates than controls.
27. Bengmark S. Synbiotics to strengthen gut barrier function and reduce morbidity in critically ill patients. Clinical Nutrition 2004; 23:441-445. This editorial on Jain et al., 2004, also covers some of the most recent studies looking at combined probiotics plus prebiotics (synbiotics) for protecting seriously ill patients from postoperative and nosocomial sepsis.
28. Gibson GR, McCartney AL, Rastall RA. Prebiotics and resistance to gastrointestinal infections. Br J Nutr 2005; 93 (Suppl 1):S31-S34.
29. Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2004; CD001321.
30. Sullivan A, Barkholt L, Nord CE. Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. J Antimicrob Chemother 2003; 52:308-311.
31. Sullivan A, Johansson A, Svenungsson B, Nord CE. Effect of Lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. J Antimicrob Chemother 2004; 54:791-797.
32. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-1623. This confirmed the findings of an earlier, smaller-scale study that the E. coli Nissle 1917 strain can be as effective and safe as mesalazine for maintaining remission.
33. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20:1133-1141.
34. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-551.
35. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52:988-997.
36. Ingrassia I, Leplingard A, Darfeuille-Michaud A. Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's Disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol 2005; 71:2880-2887.
37. Altenhoefer A, Oswald S, Sonnenborn U, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 2004; 40:223-229. These authors investigated the ability of the probiotic to reduce invasion of cultured INT407 cells by five different intestinal pathogens.
38. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004; 28:405-440. This is an excellent reference article for anyone with an interest in bacterial antagonism.
39. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol Gastrointest Liver Physiol 1999; 276:G941-G950.
40. Wehkamp J, Harder J, Wehkamp K, et al. NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004; 72:5750-5758.
41. Cross ML, Ganner A, Teilab D, Fray LM. Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria. FEMS Immunol Med Microbiol 2004; 42:173-180.
42. Hart AL, Lammers K, Brigidi P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004; 53:1602-1609. This examined the response of dendritic cells to the eight different strains within the probiotic mixture VSL#3. The mixture was a potent inducer of IL-10 by dendritic cells from intestinal tissue, with very different responses elicited by individual strains.
43. Sturm A, Rilling K, Baumgart DC, et al. Escherichia coli Nissle 1917 distinctively modulates T-Cell cycling and expansion via Toll-Like receptor 2 signaling. Infect Immun 2005; 73:1452-1465.
44. Luyer MD, Buurman WA, Hadfoune M, et al. Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun 2005; 73:3686-3692. This study emphasized the differences that can be obtained with different strains of lactobacilli on gut barrier integrity.
45. Asahara T, Shimizu K, Nomoto K, et al. Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun 2004; 72:2240-2247. Strains of several species of Bifidobacterium were tested in a mouse fatal infection model. B. breve achieved high levels of colonization, reduced toxin production, and conferred remarkable protection against death.
46. Ruiz-Perez F, Sheikh J, Davis S, et al. Use of a continuous-flow anaerobic culture to characterize enteric virulence gene expression. Infect Immun 2004; 72:3793-3802. This presents evidence that commensal and probiotic strains of bacteria can have divergent effects on expression of enteroaggregative E. coli virulence factors.
47. Parassol N, Freitas M, Thoreux K, et al. Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res Microbiol 2005; 156:256-262.
48. Verdu EF, Bercik P, Bergonzelli GE, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127:826-837.
49. Bron PA, Grangette C, Mercenier A, et al. Identification of Lactobacillus plantarum genes that are induced in the gastrointestinal tract of mice. J Bacteriol 2004; 186:5721-5729. This describes an elegant approach (R-IVET) for determining which genes are expressed during transit through the gastrointestinal tract, compared with growth on laboratory media.
50. Di Caro S, Tao H, Grillo A, et al. Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig Liver Dis 2005; 37:320-329. The study used biopsy material from six patients with oesophagitis, randomized to receive Lactobacillus GG or placebo for 1 month. Probiotic administration was associated with upregulation of 334, and downregulation of 92 genes, giving a unique insight into the complexity of the interaction between host and bacteria.
51. Sheil B, McCarthy J, O'Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004; 53:694-700. This reports an intriguing finding that subcutaneous administration of L. salivarius can attenuate colitis and collagen induced arthritis in mice. Note that, strangely, administration of heat killed bacteria resulted in 100% mortality by week 10 of the study.
52. Jiang W, Pisetsky DS. Enhancing immunogenicity by CpG DNA. Curr Opin Mol Ther 2003; 5:180-185.
53. Kitazawa H, Watanabe H, Shimosato T, et al. Immunostimulatory oligonucleotide, CpG-like motif exists in Lactobacillus delbrueckii ssp. bulgaricus NIAI B6. Int J Food Microbiol 2003; 85:11-21.
54. Lammers KM, Brigidi P, Vitali B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol 2003; 38:165-172.
55. Kamada N, Inoue N, Hisamatsu T, et al. Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 2005; 11:455-463. As well as viable cells of the E. coli strain used as a probiotic, heat killed cells or just its genomic DNA ameliorated colitis in a murine model.
56. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002; 122:1428-1441.
57. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126:520-528. This describes intriguing results, with DNA from a lab strain of E. coli, as well as from probiotic mixture VSL-#3 attenuating colitis in a mouse model. The effect was observed with both nasogastric and subcutaneously delivered DNA.
58. Reid G, Guarner F, Gibson G, et al. Discussion on toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 127:366-367. This is a lively rebuttal of Rachmilewitz et al., 2004, and the concept that probiotics could be replaced by bacterial DNA for treating gastrointestinal inflammation.
59. Steidler L. Genetically engineered probiotics. Best Pract Res Clin Gastroenterol 2003; 17:861-876.
60. Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004; 127:502-513. Trefoil factors are small, abundant secreted proteins that are cytoprotective and promote epithelial wound healing. This paper reports use of a strain of Lactococcus lactis, engineered to secrete bioactive murine trefoil factors to be highly effective for treatment of colitis in mice. This novel approach may have great potential for treating epithelial damage in humans.
61. Shanahan F. Making microbes work for mankind: clever trick or a glimpse of the future for IBD treatment? Gastroenterology 2004; 127:667-668.
62. Farrar MD, Whitehead TR, Lan J, et al. Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin-2 in response to xylan. J Appl Microbiol 2005; 98:1191 -1197. This describes an interesting approach by which an anaerobic commensal species is engineered to produce immunotherapeutic molecules, but expression can be controlled by dietary factors.
63. Westendorf AM, Gunzer F, Deppenmeier S, et al. Intestinal immunity of Escherichia coli Nissle 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005; 43:373-384.
64. 3 has been engineered. The paper reports complete protection of mice challenged with a highly virulent STEC strain producing Stx2. The approach is likely to be applicable to other toxin-mediated enteric infections, including those caused by Vibrio cholerae and Shigella dysenteriae.
65. Paton AW, Jennings MP, Morona R, et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 2005; 128:1219-1228. This describes another extension of the concept of engineering strains that express mimics of host receptors for bacterial toxins. Recombinant strain neutralised ≥93.8% of LT toxin activity of diverse enterotoxigenic E. coli. The strain can adsorb 5% of its own weight of purified toxin. A protective effect of this promising approach was demonstrated in rabbit ligated ileal loops.
66. Grozdanov L, Raasch C, Schulze J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 2004; 186:5432-5441.
67. Altermann E, Russell WM, Azcarate-Peril MA, et al. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci USA 2005; 102:3906-3912.
68. Due LH, Hong HA, Barbosa TM, et al. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004; 70:2161-2171. This is one of the few publications in this review period to evaluate the characteristics of Bacillus strains being used as probiotics. Three of the commercial strains investigated were found to produce enterotoxins.
69. von Wright A. Regulating the safety of probiotics-the European approach. Curr Pharm Des 2005; 11:17-23. This is an informative review of the current status of European Union legislation being developed to regulate the safety of probiotics used by humans.
70. Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr 2004; 79:261-267. This provides an important contribution to our understanding of the safety and tolerance of probiotic-supplemented formulas in infants. Two different concentrations of probiotics (B. lactis and Streptococcus thermophilus) were tested against placebo, and administered for 210 ± 127 days.
71. Nazli A, Yang PC, Jury J, et al. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am J Pathol 2004; 164:947-957. Using dinitrophenol to stress the intestinal epithelia of rats or human colonic cell lines (T84 and HT-29), the authors demonstrate an adverse response to commensal E. coli, including increased IL-8 production and bacterial translocation. There were important consequences for the pathophysiology of inflammatory bowel diseases, and the safety of probiotics.
72. Cherifi S, Robberecht J, Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg 2004; 59:223-224.
73. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40:1625-1634. This provides a cautionary tale of Saccharomyces fungemia developing in ICU patients receiving S. boulardii for treatment of C. difficile diarrhoea. It also reviews another 57 cases of S. cerevisiae fungaemia, and notes a significant proportion of these were epidemiologically linked to probiotic consumption.
74. Herbrecht R, Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005; 40:1635-1637.
75. Piarroux R, Millon L, Bardonnet K, et al. Are live Saccharomyces yeasts harmful to patients? Lancet 1999; 353:1851-1852.
76. Byun R, Nadkarni MA, Chhour KL, et al. Quantitative analysis of diverse Lactobacillus species present in advanced dental caries. J Clin Microbiol 2004; 42:3128-3136.
77. Montalto M, Vastola M, Marigo L, et al. Probiotic treatment increases salivary counts of lactobacilli: a double-blind, randomized, controlled study. Digestion 2004; 69:53-56. This intriguing study demonstrated that lactobacilli consumed in both liquid and capsule form can lead to an increase in salivary counts of these bacteria. The authors raise the question of whether the dental health of those taking probiotics on a long-term basis should be closely monitored.